Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a directed share issue whereby the company raised proceeds of SEK 210 million before issue costs.
The share issue was directed to a number of selected Swedish and international institutional investors on the basis of an accelerated bookbuilding process.
Vinge’s team consisted of Dain Hård Nevonen, Amanda Knutsson and Lorin Arabi.
